免疫疗法在晚期肾细胞癌中的作用：综述 - Suppr

Suppr

超能文献

The role of immunotherapy in advanced renal cell carcinoma: Review.

作者信息

Mondlane Ercília Rita, Abreu-Mendes Pedro, Martins Diana, Cruz Rui, Mendes Fernando

机构信息

Politécnico de Coimbra, ESTeSC, DFARM, ESTeSC, SM Bispo, Coimbra, Portugal.

Serviço de Urologia, Centro Hospital Universitário de São João, Porto, Portugal.

出版信息

Int Braz J Urol. 2021 Nov-Dec;47(6):1228-1242. doi: 10.1590/S1677-5538.IBJU.2020.0681.

DOI:10.1590/S1677-5538.IBJU.2020.0681

PMID:33650838

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8486460/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/279c/8486460/62403e795b92/1677-6119-ibju-47-06-1228-gf01.jpg

相似文献

The role of immunotherapy in advanced renal cell carcinoma: Review.免疫疗法在晚期肾细胞癌中的作用：综述

Int Braz J Urol. 2021 Nov-Dec;47(6):1228-1242. doi: 10.1590/S1677-5538.IBJU.2020.0681.

Immunotherapy of advanced renal cancer.晚期肾癌的免疫治疗

Eur Urol. 1990;18 Suppl 2:46-7. doi: 10.1159/000463963.

[The immunotherapy of advanced renal cell carcinoma].[晚期肾细胞癌的免疫治疗]

Dtsch Med Wochenschr. 1991 Mar 8;116(10):384-90. doi: 10.1055/s-2008-1063624.

Immunotherapy for metastatic renal cell carcinoma: a review.转移性肾细胞癌的免疫疗法：综述

Prog Clin Biol Res. 1989;303:621-7.

[Immunotherapy for advanced renal cell cancer].[晚期肾细胞癌的免疫疗法]

Urologe A. 2015 May;54(5):716-20. doi: 10.1007/s00120-015-3825-0.

Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy.晚期肾细胞癌的免疫治疗：根治性肾切除术的作用。

Eur Urol. 1990;18 Suppl 2:42-5. doi: 10.1159/000463962.

[Basic and clinical analysis of immune cell therapy against advanced renal cell carcinoma].[晚期肾细胞癌免疫细胞治疗的基础与临床分析]

Fukuoka Igaku Zasshi. 2007 Oct;98(10):357-63.

Dendritic cells for the immunotherapy of renal cell carcinoma.用于肾细胞癌免疫治疗的树突状细胞。

Urol Int. 1997;59(1):1-5. doi: 10.1159/000283008.

Immunotherapy for renal cell carcinoma.肾细胞癌的免疫疗法。

Semin Urol. 1992 Feb;10(1):23-7.

Metastasectomy plus immunotherapy compared with immunotherapy alone in metastatic renal cell carcinoma.转移性肾细胞癌中，转移灶切除术联合免疫疗法与单纯免疫疗法的比较。

Clin Oncol (R Coll Radiol). 2007 Mar;19(2):164-5. doi: 10.1016/j.clon.2006.11.001.

引用本文的文献

Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications.癌症的遗传图谱：机制、关键基因及治疗意义。

Clin Transl Oncol. 2025 Aug 17. doi: 10.1007/s12094-025-04019-4.

Decreased Expression and Secretion of the Myokine Fndc5/Irisin by Cisplatin Treatment in Mouse Skeletal Muscle.顺铂处理小鼠骨骼肌导致肌动蛋白Fndc5/鸢尾素表达和分泌减少。

Calcif Tissue Int. 2025 Jul 9;116(1):96. doi: 10.1007/s00223-025-01406-5.

Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?早期肾细胞癌：谁需要辅助治疗？

Biomedicines. 2025 Feb 21;13(3):543. doi: 10.3390/biomedicines13030543.

Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis.2000年至2017年透明细胞肾细胞癌的发病率和生存模式：一项监测、流行病学和最终结果（SEER）数据库分析

J Cancer. 2025 Feb 3;16(5):1591-1597. doi: 10.7150/jca.105713. eCollection 2025.

Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.立体定向体部放射治疗在肾癌中的应用——原发性、减瘤性和寡转移性治疗情况综述

Cancers (Basel). 2024 Sep 29;16(19):3334. doi: 10.3390/cancers16193334.

[Not Available].[无可用内容]

CMAJ. 2024 May 5;196(17):E601-E607. doi: 10.1503/cmaj.230356-f.

Advances in the management of renal cell carcinoma.肾细胞癌管理方面的进展

CMAJ. 2024 Feb 25;196(7):E235-E240. doi: 10.1503/cmaj.230356.

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA).高级透明细胞肾细胞癌管理的专家共识：印度视角（PEARL-INDIA）。

BMC Cancer. 2023 Aug 9;23(1):737. doi: 10.1186/s12885-023-11237-y.

Brief review: Applications of nanocomposite in electrochemical sensor and drugs delivery.简要综述：纳米复合材料在电化学传感器及药物递送中的应用。

Front Chem. 2023 Mar 16;11:1152217. doi: 10.3389/fchem.2023.1152217. eCollection 2023.

Research Progress of Tumor Microenvironment Targeted Therapy for Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌肿瘤微环境靶向治疗的研究进展。

Cancer Control. 2023 Jan-Dec;30:10732748231155700. doi: 10.1177/10732748231155700.

本文引用的文献

A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma.纳武单抗与阿昔替尼在转移性肾细胞癌患者总生存期、治疗持续时间及成本方面的比较研究。

Mol Clin Oncol. 2020 Mar;12(3):284-289. doi: 10.3892/mco.2020.1978. Epub 2020 Jan 16.

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.仑伐替尼联合帕博利珠单抗治疗晚期肾细胞癌、子宫内膜癌和其他选定的晚期实体瘤的 Ib/II 期临床试验。

J Clin Oncol. 2020 Apr 10;38(11):1154-1163. doi: 10.1200/JCO.19.01598. Epub 2020 Jan 21.

Preoperative serum total cholesterol is a predictor of prognosis in patients with renal cell carcinoma: a meta- analysis of observational studies.术前血清总胆固醇是预测肾细胞癌患者预后的指标：观察性研究的荟萃分析。

Int Braz J Urol. 2020 Mar-Apr;46(2):158-168. doi: 10.1590/S1677-5538.IBJU.2019.0560.

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).癌症免疫治疗学会关于免疫治疗晚期肾细胞癌（RCC）的共识声明。

J Immunother Cancer. 2019 Dec 20;7(1):354. doi: 10.1186/s40425-019-0813-8.

Colonic metastasis of renal cell carcinoma following curative nephrectomy: A case report and review of the literature.根治性肾切除术后肾细胞癌的结肠转移：一例病例报告及文献复习

Int J Surg Case Rep. 2019;65:152-155. doi: 10.1016/j.ijscr.2019.10.035. Epub 2019 Oct 23.

Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy.正常和肿瘤组织中二酰基甘油激酶的生物学调节：癌症免疫治疗的新机会。

Adv Biol Regul. 2020 Jan;75:100663. doi: 10.1016/j.jbior.2019.100663. Epub 2019 Oct 30.

Novel Immunotherapy Combinations.新型免疫疗法组合。

Curr Oncol Rep. 2019 Nov 6;21(11):96. doi: 10.1007/s11912-019-0851-x.

Peptide-based materials for cancer immunotherapy.基于肽的癌症免疫疗法材料。

Theranostics. 2019 Oct 15;9(25):7807-7825. doi: 10.7150/thno.37194. eCollection 2019.

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.avelumab 单药治疗作为转移性肾细胞癌一线或二线治疗：JAVELIN 实体瘤试验的 Ib 期结果。

J Immunother Cancer. 2019 Oct 24;7(1):275. doi: 10.1186/s40425-019-0746-2.

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于既往未治疗的晚期肾细胞癌：CheckMate 214 研究中日本患者的分析结果，随访时间延长。

Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验